Nevro Introduces HFX, New Comprehensive Brand Identity Combining Nevro's Innovative Technologies, Advanced Therapies and End-to-End Patient Support

REDWOOD CITY, Calif., April 26, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today  announced the introduction of its new HFX brand and updated website, which is designed to unify its products and services to optimize the physician and patient experience.  The introduction of the HFX brand platform includes the full U.S. market launch of the company's recent Omnia upgrade (powered by HFX Connect) and additional patient support resources (HFX Coach™, formerly called Therapy Support Specialists) who are trained in remote therapy optimization. 

"Today we are known for our highly differentiated SCS products, but the value our technology provides to patients and customers is really far greater," said Niamh Pellegrini, Chief Commercial Officer of Nevro.  "Under our new HFX brand identity, we will be able to bring products, services and support together under one cohesive, durable framework that supports today's solutions and tomorrow's new offerings, whether they are new products, innovations in waveforms and frequencies, services, clinical data, or our unique forms of patient and customer support."

HFX gives Nevro the ability to bring together its innovative technologies, advanced therapies and end-to-end support services, all of which are built on an industry-leading foundation of robust clinical data.  For physicians, HFX technologies and advanced therapies offer the broadest range of frequencies and waveforms, including Nevro's proprietary 10 kHz therapy, which has demonstrated superior back and leg pain relief versus traditional spinal cord stimulation (SCS) and is the most studied waveform in the industry.  

"The Omnia upgrade, now powered by HFX Connect, has enhanced my ability to remotely support patients, especially during the pandemic," said Bryan C. Hoelzer, MD, anesthesiologist, pain specialist and former Director of Neuromodulation and the Pain Medicine Fellowship at the Mayo Clinic in Rochester.  "It includes more customizable programs and a richer approach to optimizing therapy that is informed by Nevro's large patient database. It has helped me reliably get relief for my patients."

HFX Connect: Continuing Innovation for Individualized Therapy and Patient Support

Omnia powered by HFX Connect, provides the widest array of SCS frequencies and waveforms, which can now also be delivered remotely by HFX Coaches to meet every patient's needs.  HFX Connect is universally compatible with both new and previously implanted Omnia systems.

• HFX Connect enables remote patient therapy optimization that leverages a data-driven programming approach informed by over 70,000 patient outcomes. With 7x more programming capacity, the system now delivers more versatility and therapy optimization without in-person visits. 
   
• Exclusive HFX Cloud™ enables real-time, data-informed patient care by tracking and sharing each patient's specific therapy outcomes with the patient's physician and HFX support team.
   
• Dedicated HFX Coaches provide remote, individualized patient therapy support, from pre-trial education to long-term success. In addition to existing Nevro in-person representatives, HFX Coaches deliver an industry-leading number of proactive and on-demand patient touchpoints.
    
• Remote system diagnostics, available to both Omnia and legacy Nevro SCS patients, allow health care providers to more efficiently evaluate systems and facilitate MRI scans.

All new Omnia implants include HFX Connect, and the company plans to upgrade the majority of existing Omnia devices by the end of 2021.  The company expects full market release of Omnia powered by HFX Connect in Australia later next month and regulatory approval in Europe later this year.

Internet Posting of Information 

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com.  The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro. 

About Nevro 

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain.  Nevro's proprietary 10 kHz therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies.  The Senza^® System, Senza II™ System, and the Senza^® Omnia™ System are the only SCS systems that deliver Nevro's proprietary 10 kHz therapy.  

SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, HFX, the HFX logo, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram. 

Forward-Looking Statements  

In addition to historical information, this press release contains forward-looking statements reflecting the company's current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: our plans to upgrade the majority of existing Omnia devices by the end of 2021; and our expectation of the full market release of Omnia powered by HFX Connect in Australia later next month and regulatory approval in Europe later this year.  These forward-looking statements are based upon information that is currently available to us or our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully commercialize our products; our ability to manufacture our products to meet demand; the level and availability of third-party payor reimbursement for our products; our ability to effectively manage our anticipated growth and the costs and expenses of operating our business; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims.  These factors, together with those that are described in greater detail in our Annual Report on Form 10-K filed on February 24, 2021, as well as any reports that we may file with the Securities and Exchange Commission in the future, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements.  We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Vice President, Investor Relations & Corp Communications
650-433-3247  |  [email protected]  

SOURCE Nevro Corp.

Related Links

http://www.nevro.com